SymBio Pharmaceuticals Limited (SYMQY)

SymBio Pharmaceuticals Limited (SYMQY) Healthcare & Pipeline Overview

SymBio Pharmaceuticals Limited, headquartered in Tokyo, is a Japanese pharmaceutical company established in 2005. It specializes in developing and commercializing oncology and hematology therapeutics, with a core focus on its anticancer agent Treakisym and a pipeline addressing non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and higher-risk myelodysplastic syndromes.

What Is the Investment Thesis for SYMQY?

SymBio Pharmaceuticals Limited presents a research-driven profile centered on specialized oncology and hematology therapeutics, underpinned by its established product, Treakisym, and a robust pipeline. The company's current market capitalization stands at $0.03 billion, reflecting its niche focus and development stage. A key value driver is the potential expansion of Treakisym's indications, particularly its ongoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma, which could significantly broaden its market reach. Further growth catalysts include the advancement of novel formulations like SyB L-1701 and SyB L-1702, designed to improve drug delivery and patient experience. The pipeline also features SyB L-1101 (intravenous) and SyB C-1101 (oral) for higher-risk myelodysplastic syndromes, both in advanced clinical stages, representing significant future revenue potential if approved. However, the company faces an ongoing challenge with a profit margin of -458.6%, indicating substantial investment in R&D and commercialization efforts relative to current profitability. The gross margin of 71.9% suggests strong pricing power for its products, but overall profitability remains a critical area for improvement. The inherent risks of drug development, including clinical trial failures and regulatory hurdles, are significant considerations for this specialized pharmaceutical entity.

Based on FMP financials and quantitative analysis

SYMQY Key Highlights

• SymBio Pharmaceuticals Limited maintains a focused market capitalization of $26.38M, reflecting its specialized position within the pharmaceutical sector.
• The company reported a gross margin of 71.9%, indicating strong pricing power and cost control over its core pharmaceutical products.
• A significant negative profit margin of -458.6% highlights the substantial ongoing investments in research, development, and commercialization activities, typical for a biotech company with a developing pipeline.
• With a Beta of 0.44, SymBio Pharmaceuticals Limited demonstrates lower volatility compared to the broader market, suggesting a relatively stable stock performance.
• The company employs 108 individuals, indicating a lean and specialized operational structure focused on its core therapeutic areas of oncology and hematology.

Who Are SYMQY's Competitors?

SYMQY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYMQY's Key Strengths?

• Established flagship product, Treakisym, with multiple approved indications in oncology and hematology.
• Robust pipeline with several drug candidates in advanced clinical trial stages (Phase II/III) for high-need conditions like HR-MDS and new Treakisym indications.
• Specialized focus on oncology and hematology, allowing for deep expertise and targeted market penetration.
• High gross margin of 71.9%, indicating strong pricing power and efficient production for its commercialized product.
• Development of enhanced formulations (ready-to-dilute, rapid infusion) aiming to improve patient convenience and market adoption.

What Are SYMQY's Weaknesses?

• Significant negative profit margin of -458.6%, indicating substantial unprofitability and reliance on funding for R&D.
• Dependence on a limited product portfolio, with Treakisym being the primary commercialized asset.
• High inherent risks associated with drug development, including potential for clinical trial failures and regulatory setbacks.
• Small market capitalization of $26.38M, which may limit access to capital compared to larger pharmaceutical companies.
• Operating in a highly competitive industry against larger, more resourced pharmaceutical companies.

What Could Drive SYMQY Stock Higher?

• Positive results and regulatory approval for Treakisym in Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma, expected within the next 1-2 years.
• Successful advancement and potential regulatory approval of SyB L-1101 (intravenous) for higher-risk myelodysplastic syndromes (HR-MDS) from Phase III trials, anticipated within 2-3 years.
• Positive data and regulatory progression for SyB C-1101 (oral) in Phase II/III clinical trials for HR-MDS in combination with Azacitidine, potentially leading to market entry within 3-5 years.
• Continued development and potential market introduction of enhanced Treakisym formulations (SyB L-1701 and SyB L-1702), which could improve patient convenience and market share.
• Progress in the development of SyB V-1901, an antiviral medication, indicating diversification and potential entry into new therapeutic markets in the longer term.

What Are the Key Risks for SYMQY?

• Financial-distress signal — its Altman Z-Score of -23.87 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of Treakisym's ongoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma, which would limit its market expansion.
• Significant negative profit margin of -458.6%, indicating a substantial burn rate and reliance on future product approvals for profitability.
• Clinical trial failures or unexpected safety issues for pipeline candidates like SyB L-1101, SyB C-1101, or SyB V-1901, leading to delays or abandonment of development.
• Intense competition within the oncology and hematology markets from larger pharmaceutical companies with greater financial and R&D resources.
• Regulatory delays or non-approvals from health authorities in key markets, impacting the commercialization timeline and revenue generation for new drugs or indications.

What Are the Growth Opportunities for SYMQY?

• Growth opportunity 1: Expansion of Treakisym's Approved Indications. SymBio Pharmaceuticals is currently advancing Treakisym (SyB L-0501) through Phase III clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Successful approval for this additional indication would significantly expand the addressable patient population for SymBio's flagship product. The global market for lymphoma treatments is substantial and growing, driven by increasing incidence rates and the need for more effective therapies for refractory cases. A positive outcome in these trials could unlock a new revenue stream within the next 2-4 years, leveraging the established commercial infrastructure for Treakisym.
• Growth opportunity 2: Development of Enhanced Treakisym Formulations. The company is actively developing SyB L-1701 as a ready-to-dilute formulation and SyB L-1702 as a rapid infusion liquid formulation of Treakisym. These advancements aim to improve convenience for both healthcare providers and patients, potentially leading to increased adoption and market share. Enhanced formulations can differentiate a product in a competitive landscape, offering practical benefits such as reduced preparation time or shorter administration duration. These developments, likely targeting market entry within the next 1-3 years post-approval, could solidify Treakisym's position and extend its product lifecycle.
• Growth opportunity 3: Advancement of SyB L-1101 for Higher-Risk Myelodysplastic Syndromes (HR-MDS). SymBio's pipeline includes SyB L-1101, an intravenous drug undergoing Phase III trials for HR-MDS. HR-MDS represents a critical unmet medical need with limited effective treatment options, making it a high-value target market. Successful development and commercialization of SyB L-1101 would provide SymBio with a significant new product in a specialized oncology segment. The global market for MDS therapies is projected to grow, driven by an aging population and diagnostic improvements. This drug could become a key revenue driver within a 3-5 year timeframe following successful trials and regulatory clearance.
• Growth opportunity 4: Development of Oral SyB C-1101 for HR-MDS. Concurrently, SymBio is progressing SyB C-1101, an oral formulation, through Phase II/III clinical trials for HR-MDS when administered in combination with Azacitidine. An oral therapy for HR-MDS offers substantial advantages in terms of patient convenience and potential for outpatient administration, which can improve adherence and quality of life. This could capture a significant portion of the HR-MDS market, especially for patients seeking less invasive treatment options. The development of an oral alternative to existing intravenous therapies could provide a competitive edge, with potential market entry within 3-5 years.
• Growth opportunity 5: Diversification into Antiviral Therapeutics with SyB V-1901. SymBio is also developing SyB V-1901, an antiviral medication targeting infectious diseases. This represents a strategic diversification beyond its primary oncology and hematology focus, potentially opening new market segments for the company. The global market for antiviral drugs is vast and continually evolving, driven by emerging pathogens and the need for effective treatments for chronic viral infections. While specific indications are not detailed, a successful antiviral drug could provide a complementary revenue stream and mitigate reliance on a single therapeutic area, with a longer-term development horizon, likely 5+ years for significant market impact.

What Opportunities Does SYMQY Have?

• Successful approval and commercialization of Treakisym for relapsed/refractory diffuse large B-cell lymphoma, expanding its market.
• Successful development and launch of SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes, addressing a significant unmet medical need.
• Market penetration and adoption of new Treakisym formulations (SyB L-1701, SyB L-1702) due to improved patient convenience.
• Diversification into antiviral therapeutics with SyB V-1901, opening new market segments and revenue streams.
• Potential for strategic partnerships or licensing agreements to accelerate development or expand commercial reach in new geographies.

What Threats Does SYMQY Face?

• Failure of ongoing clinical trials for pipeline candidates or new indications to meet efficacy or safety endpoints.
• Intense competition from other pharmaceutical companies developing similar or superior treatments in oncology and hematology.
• Regulatory hurdles and delays in obtaining approvals for new drugs or indications, impacting time to market and revenue generation.
• Patent expirations or loss of market exclusivity for Treakisym, leading to generic competition and reduced profitability.
• Adverse changes in healthcare policies, reimbursement landscapes, or drug pricing regulations in key markets.

What Are SYMQY's Competitive Advantages?

• Proprietary drug development and intellectual property surrounding its existing product, Treakisym, and its pipeline candidates.
• Specialized focus on oncology and hematology, creating expertise and relationships within these niche therapeutic areas.
• Regulatory approvals and market exclusivity for its approved indications provide a temporary barrier to entry for competitors.
• Ongoing clinical trials for new indications and formulations of Treakisym, which could extend its market presence and utility.
• The inherent complexity and high cost of drug development and regulatory approval processes act as a significant barrier for new entrants.

What Does SYMQY Do?

SymBio Pharmaceuticals Limited, a Japanese pharmaceutical company, was founded in 2005 and is headquartered in Tokyo, Japan. The company's core expertise lies in the comprehensive lifecycle of pharmaceutical products, encompassing research, development, manufacturing, and commercialization, with a strategic focus on the critical therapeutic areas of oncology and hematology. A cornerstone of SymBio's product portfolio is the anticancer agent Treakisym SyB L-0501, widely marketed under the brand name TREAKISYM. This essential medication is specifically indicated for the treatment of several severe hematological malignancies, including non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, addressing significant unmet medical needs within these patient populations. Beyond its established product, SymBio is actively engaged in expanding the utility of TREAKISYM, with the drug currently undergoing Phase III clinical trials for a new indication: the treatment of relapsed/refractory diffuse large B-cell lymphoma. This ongoing development highlights the company's commitment to maximizing the therapeutic reach of its flagship product. Furthermore, SymBio's pipeline extends to advanced formulations of existing treatments, such as SyB L-1701, which is being developed as a ready-to-dilute formulation, and SyB L-1702, a rapid infusion liquid formulation, both designed to enhance patient convenience and administration efficiency. The company's commitment to innovation is also evident in its development of SyB L-1101, an intravenous drug currently in Phase III trials for higher-risk myelodysplastic syndromes (HR-MDS), a challenging condition requiring advanced therapeutic options. Complementing this, SymBio is also progressing SyB C-1101, an oral formulation, through Phase II/III clinical trials for HR-MDS when administered in combination with Azacitidine, offering a potentially more accessible treatment modality. Diversifying its therapeutic scope, SymBio is also developing SyB V-1901, an antiviral medication aimed at addressing infectious diseases, demonstrating a broader strategic vision beyond its primary oncology and hematology focus.

What Products and Services Does SYMQY Offer?

• Research and develop pharmaceutical products primarily for oncology and hematology.
• Manufacture anticancer agents like Treakisym SyB L-0501 (TREAKISYM).
• Commercialize TREAKISYM for non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia.
• Conduct Phase III clinical trials for TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma.
• Develop advanced formulations such as SyB L-1701 (ready-to-dilute) and SyB L-1702 (rapid infusion liquid).
• Advance SyB L-1101, an intravenous drug, through Phase III trials for higher-risk myelodysplastic syndromes (HR-MDS).
• Progress SyB C-1101, an oral formulation, through Phase II/III clinical trials for HR-MDS in combination with Azacitidine.
• Develop SyB V-1901, an antiviral medication targeting infectious diseases.

How Does SYMQY Make Money?

• Generate revenue through the sales and commercialization of its approved pharmaceutical product, TREAKISYM, for various oncology and hematology indications.
• Invest heavily in research and development to discover, develop, and bring new drug candidates to market, aiming for future revenue streams from pipeline products.
• Potentially license out or partner with larger pharmaceutical companies for the commercialization of its drugs in specific regions, leveraging their distribution networks.
• Focus on specialized therapeutic areas with high unmet medical needs, allowing for premium pricing upon successful market entry of innovative treatments.
• Seek regulatory approvals for new indications and improved formulations of existing drugs to expand market reach and extend product lifecycles.

What Industry Does SYMQY Operate In?

SymBio Pharmaceuticals Limited operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by significant R&D investment, stringent regulatory pathways, and a strong emphasis on intellectual property. SymBio's focus on oncology and hematology positions it within a high-growth, high-need market segment, where demand for innovative treatments remains robust due to increasing disease prevalence and evolving treatment paradigms. The competitive landscape includes both large multinational pharmaceutical corporations with extensive resources and smaller, agile biotech firms specializing in niche therapeutic areas. Market trends indicate a shift towards personalized medicine, targeted therapies, and improved drug delivery systems, areas where SymBio's pipeline, including new formulations and specific indications for Treakisym, aligns. The company's strategy of developing treatments for conditions like non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and higher-risk myelodysplastic syndromes places it in direct competition for market share against established and emerging therapies, necessitating continuous innovation and successful clinical execution.

Who Are SYMQY's Key Customers?

• Oncology and hematology specialists and physicians who prescribe treatments for cancer and blood disorders.
• Hospitals, clinics, and healthcare institutions that administer pharmaceutical products to patients.
• Patients suffering from non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and higher-risk myelodysplastic syndromes.
• Pharmacists and pharmaceutical distributors who manage the supply chain of specialized medications.
• Potentially patients with infectious diseases, upon successful development and commercialization of antiviral products.

F-Score 2/9Financial Health

SymBio Pharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.87 places it in the distress zone, a signal of elevated financial risk.

SYMQY Valuation & Market Position

With a $26.38M market cap, SymBio Pharmaceuticals Limited sits in the micro-cap segment of the market. Relative to its peer group, SYMQY's quantitative score of 53/100 is below the peer average of 66/100.

Key Financial Metrics

Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -118.3%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

SymBio Pharmaceuticals Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Fuminori Yoshida. SYMQY has traded publicly since 2016.

SYMQY Financials

SYMQY Latest News

No recent news available for SYMQY.

SYMQY Analyst Consensus

SYMQY MoonshotScore

What Investors Ask About SymBio Pharmaceuticals Limited (SYMQY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources